Adipose Metabolic Control in the Gerhart-Hines Group

"Lipolysis drives expression of the constitutively active receptor GPR3 to induce adipose thermogenesis"
Published in Cell in 2021. G protein-coupled receptors (GPCR) are classically regulated by the binding of a soluble ligand. In this study, we found that the constitutively active receptor, GPR3, was instead regulated at the transcriptional level by a noncanonical signal from lipolysis in brown adipocytes. Upon reaching the cell surface, GPR3 begins signalling through Gs proteins to increase cAMP levels without the apparent need of a ligand. Thus, increasing Gpr3 expression is fully sufficient to drive the downstream hallmarks of thermogenesis in mouse and human adipocytes. These findings open up new avenues through which we hope to harness and engineer adipose metabolism for therapeutic purposes.

“NAMPT-mediated NAD+ biosynthesis is indispensable for adipose tissue plasticity and development of obesity”
Published in Molecular Metabolism in 2018. In this study, we show for the first time that the NAD+ biosynthetic enzyme, NAMPT, is an essential regulator of adipose expansion. Genetic depletion of NAMPT in adipose tissue completely prevents mice from gaining weight and becoming obese even on a diet rich in fat.

“Cardiolipin Synthesis Governs Systemic Energy Homeostasis through Thermogenic Fat Mitochondria”
Published in Cell Metabolism in 2018. In this study, we found that synthesis of the mitochondrial phospholipid cardiolipin is indispensable for stimulating and sustaining thermogenic fat function. Additionally, we unexpectedly discovered a novel role for cardiolipin in mediating communication from the mitochondria to the nucleus as an indicator of respiratory capacity. Finally, this was the first study to demonstrate that acute mitochondrial dysfunction in brown fat caused whole-body insulin resistance.

"A novel endocrine axis that potently induces energy expenditure and weight loss"
Our investigation of adipose energy-expending pathways led to the discovery of a new regulator of organismal homeostasis. Targeting this pathway is capable of counteracting obesity and related disorders in rodent models of metabolic disease. In 2018, we spun out Embark Biotech from the University of Copenhagen to fully explore the innovative potential of this candidate as an obesity drug.